A bright future of researching AMPA receptor agonists for depression treatment

  title={A bright future of researching AMPA receptor agonists for depression treatment},
  author={Chun Yang and Wei Zhou and Xiaoming Li and Jianjun Yang and Bernadeta Szewczyk and Agnieszka Pałucha-Poniewiera and Ewa Poleszak and Andrzej Pilc and Gabriel Nowak},
  journal={Expert Opinion on Investigational Drugs},
  pages={583 - 585}
  • Chun Yang, W. Zhou, G. Nowak
  • Published 12 April 2012
  • Psychology, Biology
  • Expert Opinion on Investigational Drugs
Ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, is a widely used drug for anesthesia. However, increasing studies have focused on the potential antidepressant effects of ketamine. As mentioned in the review of Szewczyk et al. [1], subunit selective NMDA receptor antagonists exert the same antidepressant efficacy of ketamine but with fewer adverse effects. Indeed, the authors make a good comment and indicate a bright research future of developing novel antidepressants. However, we… 
4 Citations
NMDA receptor antagonists for depression: Critical considerations.
  • G. SerafiniX. Gonda M. Amore
  • Psychology, Biology
    Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists
  • 2015
Targeting NMDARs using antagonists represents an important alternative antidepressant option in major depression, however, N MDAR antagonists may exert different actions based on the differential brain location of NMDar.
Au-delà des antidépresseurs sérotoninergiques... nouvelles stratégies pharmacologiques
Although mood disorders such as depression are better diagnosed, their treatment often remains unsatisfactory. Pharmacological treatments of depression mostly target the central monoaminergic
Enantiopure methoxetamine stereoisomers: chiral resolution, conformational analysis, UV-circular dichroism spectroscopy and electronic circular dichroism
Enantioseparation and assignment of absolute configuration of methoxetamine (MXE) enantiopure stereoisomers; a promising novel antidepressant for management of treatment-resistant depression.


Investigational NMDA receptor modulators for depression
Ketamine has become a standard tool for identifying the biological factors associated with rapid antidepressant action and, as such, is a novel target for the development of new therapeutics.
AMPA receptors in the therapeutic management of depression.
Data from mutant mice suggest that AMPA receptors may regulate the expression of brain-derived neurotrophic factor, a neurotrophin which has been implicated in the actions of antidepressant therapies, and that compounds which target AMPA receptor receptors may prove useful in the clinical management of depression.
The involvement of NMDA and AMPA receptors in the mechanism of antidepressant-like action of zinc in the forced swim test
Zinc administration potentiated a veratridine-evoked glutamate and aspartate release in the rat’s prefrontal cortex and hippocampus and indicates the involvement of the NMDA and AMPA glutamatergic receptors in this activity.
On the mechanism of the antidepressant-like action of group II mGlu receptor antagonist, MGS0039
It is found that repeated administration of MGS0039 attenuated OB-related deficits, confirming antidepressant-like activity of the tested compound, and the mechanism of action of group II mGlu receptor antagonists differs from that of typical antidepressants, such as SSRIs.